- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06075602
COMPLEX Registry - A Prospective COhort Study to Describe the Management and Outcomes of Patients Presenting With compLEX and Calcified Coronary Artery Disease (COMPLEX)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
a. PCI cohort - Periprocedural outcomes/ complications to be analyzed represent: final result (e.g. TIMI flow), stent expansion, dissections, perforations, and prevalence of thrombus (assessed by angiography and intravascular imaging) b. CABG cohort - Periprocedural outcomes/ complications to be analyzed include: final result (e.g. graft flow), number and type of grafts, total length of surgery, bypass time, cross-clamp time, median chest-tube output (mL), bleeding, duration of CCU/ ICU stay, re-operation.
c. For the PCI, CABG as well as medically managed cohort, short and long-term clinical outcomes of interest include: unstable angina (UA), stent-/scaffold thrombosis, target lesion failure (TLF), target vessel revascularization (TVR), ischemia driven revascularization, repeat hospitalization, new/worsening heart failure, cardiogenic shock, stroke, bleedings, cardiovascular death and all-cause death.
2. PCI cohort:
- To describe procedural and clinical performance of various PCI devices including high pressure balloons, scoring, balloons, cutting balloons, rotational atherectomy, orbital atherectomy, intravascular lithotripsy, stent and scaffold devices implanted in patients presenting with complex and calcified chronic CAD
- To study the impact of different PCI devices and revascularization strategies used for lesion preparation and PCI optimization strategies among patients undergoing PCI
- To describe early and late angiographic and OCT-findings among complex and calcified coronary artery disease patients treated with various metallic stent and scaffold devices
- To assess possible predictors for coronary stent implantation or device failure 3. CABG cohort:
a. To describe procedural and clinical performance of various surgical techniques b. To assess outcomes across various surgical cohorts (e.g. urgent vs. elective, diabetic vs. non-diabetic, gender disparities) c. To investigate various CABG revascularization strategies (e.g. off- versus on-pump, "Fully arterial", minimal invasive approach) and their impact on short and long-term outcomes d. To describe perioperative recovery and risk for in-hospital complications (e.g. wound infections, pneumonia) e. To assess possible predictors for graft failure with contemporary surgical techniques 4. Conservative - only medically treated - cohort:
- To describe medical management (drugs regimens) as well as other lifestyle interventions in patients presenting with complex and calcified chronic CAD who are being treated with a primarily conservative (non-invasive) strategy.
- To study the clinical impact of different treatment strategies/ medical regimens used among chronic, complex CAD, which are being managed solely with medical therapy.
To assess possible predictors for management failure (e.g. recurrence of symptoms or impaired quality of life).
5. To compare presentation, (medical) management, short- and long-term outcomes across the different treatment cohorts (PCI, CABG and medically managed cohort).
6. To specifically describe age- and gender-specific disparities across the various treatment regimens (e.g. PCI versus CABG).
7. To evaluate the impact of different antithrombotic regimens on patient's clinical outcomes 8. To study procedural and clinical outcomes among CAD patients requiring hemodynamic support using mechanical devices.
9. To analyze the performance of various non-invasive testing modalities (e.g. laboratory/ ECG parameters, treadmill-test, stress-echocardiography, CMR, SPECT or PET-CT) in order to predict outcomes of patients with chronic, complex CAD.
10. To describe economic implications (cost-effectiveness) of various interventional treatments for CAD.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Matthias Bossard, MD
- Phone Number: +41412051477
- Email: matthias.bossard@luks.ch
Study Contact Backup
- Name: Florim Cuculi, MD
- Phone Number: +41412052154
- Email: florim.cuculi@luks.ch
Study Locations
-
-
-
Lucerne, Switzerland, 6000
- Recruiting
- Lucerne Heart Centre
-
Contact:
- Florim Cuculi, MD
- Phone Number: +41412052154
- Email: florim.cuculi@luks.ch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subject >18 years of age
- Individuals presenting with chronic, complex and/or calcified CAD and requiring PCI or CABG
- Complex coronary artery disease / lesions must include at least one of the following attributes:
- Long and/ or heavily calcified coronary lesions
- In-stent restenosis
- Chronic total occlusions (CTO)
- Left main lesions
- Bifurcation lesions
- Bypass graft lesions
- Small vessel disease / coronary microvascular dysfunction (e.g. not amenable to PCI)
- Subjects must be willing to sign a patient informed consent (PIC) or must have signed the General Consent (GK).
Exclusion Criteria:
The presence of any one of the following exclusion criteria will lead to exclusion of the patient.
- Patient is <18 years of age
- Patient unwilling or unable to provide informed consent
- Patients with no complex and calcified CAD
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Treatment
The project ́s main goal is to collect baseline, clinical and procedural data as well as to assess angiographic and clinical outcomes of patients with complex coronary lesions treated with current PCI techniques/ devices, but also CABG strategies in different clinical settings.
|
To evaluate the impact of current PCI techniques/devices, but also CABG strategies, in patients with complex coronary artery lesions
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of Major adverse cardiac and cerebrovascular events (MACCE)
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of combination of major adverse cardiac and cerebrovascular events (MACCE)
Time Frame: 1 year, 2 years, 5 years and 10 years
|
1 year, 2 years, 5 years and 10 years
|
Rate of acute vessel closure
Time Frame: 1 year, 2 years, 5 years and 10 years
|
1 year, 2 years, 5 years and 10 years
|
Rate of target vessel revascularization (TVR)
Time Frame: 1 year, 2 years, 5 years and 10 years
|
1 year, 2 years, 5 years and 10 years
|
Rate of target lesion revascularization (TLR)
Time Frame: 1 year, 2 years, 5 years and 10 years
|
1 year, 2 years, 5 years and 10 years
|
Rate of target lesion failure (TLF)
Time Frame: 1 year, 2 years, 5 years and 10 years
|
1 year, 2 years, 5 years and 10 years
|
Rate of ischemia driven TLR
Time Frame: 1 year, 2 years, 5 years and 10 years
|
1 year, 2 years, 5 years and 10 years
|
Rate of new AMI (NSTEMI/STEMI)
Time Frame: 1 year, 2 years, 5 years and 10 years
|
1 year, 2 years, 5 years and 10 years
|
Rate of TIA or stroke
Time Frame: 1 year, 2 years, 5 years and 10 years
|
1 year, 2 years, 5 years and 10 years
|
Rate of cardiovascular mortality
Time Frame: 1 year, 2 years, 5 years and 10 years
|
1 year, 2 years, 5 years and 10 years
|
Rate of all-cause mortality
Time Frame: 1 year, 2 years, 5 years and 10 years
|
1 year, 2 years, 5 years and 10 years
|
Rate of bleeding events (access site or non-access site related) according to the BARC classification.
Time Frame: 1 year, 2 years, 5 years and 10 years
|
1 year, 2 years, 5 years and 10 years
|
Rate of vascular complications (according to VARC criteria)
Time Frame: 1 year, 2 years, 5 years and 10 years
|
1 year, 2 years, 5 years and 10 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Florim Cuculi, MD, Luzerner Kantonsspital
Publications and helpful links
General Publications
- Seiler T, Attinger-Toller A, Cioffi GM, Madanchi M, Teufer M, Wolfrum M, Moccetti F, Toggweiler S, Kobza R, Bossard M, Cuculi F. Treatment of In-Stent Restenosis Using a Dedicated Super High-Pressure Balloon. Cardiovasc Revasc Med. 2023 Jan;46:29-35. doi: 10.1016/j.carrev.2022.08.018. Epub 2022 Aug 20.
- Madanchi M, Cioffi GM, Attinger-Toller A, Wolfrum M, Moccetti F, Seiler T, Vercelli L, Burkart P, Toggweiler S, Kobza R, Bossard M, Cuculi F. Long-term outcomes after treatment of in-stent restenosis using the Absorb everolimus-eluting bioresorbable scaffold. Open Heart. 2021 Sep;8(2):e001776. doi: 10.1136/openhrt-2021-001776.
- Pinilla-Echeverri N, Bossard M, Hillani A, Chavarria JA, Cioffi GM, Dutra G, Guerrero F, Madanchi M, Attinger A, Kossmann E, Sibbald M, Cuculi F, Sheth T. Treatment of Calcified Lesions Using a Dedicated Super-High Pressure Balloon: Multicenter Optical Coherence Tomography Registry. Cardiovasc Revasc Med. 2023 Jul;52:49-58. doi: 10.1016/j.carrev.2023.02.020. Epub 2023 Mar 2.
- Madanchi M, Cioffi GM, Kobza R, Cuculi F, Bossard M. The Importance of Defining the Coronary Anatomy in Suspected Myopericarditis: A Case Report. Am J Case Rep. 2021 Mar 29;22:e929009. doi: 10.12659/AJCR.929009.
- Bossard M, Madanchi M, Avdijaj D, Attinger-Toller A, Cioffi GM, Seiler T, Tersalvi G, Kobza R, Schupfer G, Cuculi F. Long-Term Outcomes After Implantation of Magnesium-Based Bioresorbable Scaffolds-Insights From an All-Comer Registry. Front Cardiovasc Med. 2022 Apr 14;9:856930. doi: 10.3389/fcvm.2022.856930. eCollection 2022.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arterial Occlusive Diseases
- Pain
- Neurologic Manifestations
- Embolism and Thrombosis
- Chest Pain
- Coronary Stenosis
- Coronary Artery Disease
- Myocardial Ischemia
- Coronary Disease
- Thrombosis
- Arteriosclerosis
- Angina Pectoris
- Angina, Stable
- Angina, Unstable
- Coronary Restenosis
Other Study ID Numbers
- 2021-01290
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Impact of current PCI techniques/ devices in complex coronary artery lesions
-
University Heart Center Freiburg - Bad KrozingenCordis, Johnson&Johnson companyUnknown